CN112409285A - 噁唑烷酮类化合物的晶型及其制备方法和应用 - Google Patents
噁唑烷酮类化合物的晶型及其制备方法和应用 Download PDFInfo
- Publication number
- CN112409285A CN112409285A CN202011370984.4A CN202011370984A CN112409285A CN 112409285 A CN112409285 A CN 112409285A CN 202011370984 A CN202011370984 A CN 202011370984A CN 112409285 A CN112409285 A CN 112409285A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- fluoro
- oxazolidinyl
- oxo
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 oxazolidinone compound Chemical class 0.000 title claims abstract description 101
- 239000013078 crystal Substances 0.000 title claims abstract description 82
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical group CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims abstract description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000002076 thermal analysis method Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010014889 Enterococcal infections Diseases 0.000 description 2
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011370984.4A CN112409285A (zh) | 2020-11-30 | 2020-11-30 | 噁唑烷酮类化合物的晶型及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011370984.4A CN112409285A (zh) | 2020-11-30 | 2020-11-30 | 噁唑烷酮类化合物的晶型及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112409285A true CN112409285A (zh) | 2021-02-26 |
Family
ID=74830543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011370984.4A Pending CN112409285A (zh) | 2020-11-30 | 2020-11-30 | 噁唑烷酮类化合物的晶型及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112409285A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200100010A1 (ru) * | 1998-06-05 | 2001-06-25 | Фармация Энд Апджон Компани | Местное применение оксазолидинонов для трансдермальной доставки |
CN102174027A (zh) * | 2010-03-11 | 2011-09-07 | 成都自豪药业有限公司 | 利奈唑胺的新晶型及其制备方法和用途 |
CN102256951A (zh) * | 2009-11-04 | 2011-11-23 | 四川贝力克生物技术有限责任公司 | 结晶水合物、药物组合物及其制备方法和用途 |
CN107286111A (zh) * | 2016-03-30 | 2017-10-24 | 四川赛卓药业股份有限公司 | 一种噁唑烷酮化合物的制备方法 |
-
2020
- 2020-11-30 CN CN202011370984.4A patent/CN112409285A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200100010A1 (ru) * | 1998-06-05 | 2001-06-25 | Фармация Энд Апджон Компани | Местное применение оксазолидинонов для трансдермальной доставки |
CN102256951A (zh) * | 2009-11-04 | 2011-11-23 | 四川贝力克生物技术有限责任公司 | 结晶水合物、药物组合物及其制备方法和用途 |
CN102174027A (zh) * | 2010-03-11 | 2011-09-07 | 成都自豪药业有限公司 | 利奈唑胺的新晶型及其制备方法和用途 |
CN107286111A (zh) * | 2016-03-30 | 2017-10-24 | 四川赛卓药业股份有限公司 | 一种噁唑烷酮化合物的制备方法 |
Non-Patent Citations (1)
Title |
---|
赵临襄: "《化学制药工艺学》", 31 December 2015 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1440969A1 (en) | Alpha-form or beta-form crystal of acetanilide derivative | |
RO119782B1 (ro) | Monohidrat de cdch, procedeu pentru prepararea sa şi compoziţii farmaceutice care îl conţin | |
CN112142679B (zh) | 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法 | |
JP2017061578A (ja) | 有機化合物 | |
CN111187253A (zh) | 一种阿昔替尼新晶型 | |
JP6957807B2 (ja) | 右旋性オキシラセタムの2型結晶、調製方法および用途 | |
CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
CN111205290B (zh) | 一种jak激酶抑制剂的结晶形式及其制备方法 | |
CN102942577B (zh) | 一种含有头孢西丁钠化合物的药物组合物 | |
CN102256951B (zh) | 结晶水合物、药物组合物及其用途 | |
CN112409285A (zh) | 噁唑烷酮类化合物的晶型及其制备方法和应用 | |
CN106008277A (zh) | 一种新型二甲双胍盐酸盐及其制备方法 | |
WO2017096907A1 (zh) | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 | |
CA2596754C (en) | Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders | |
TWI762825B (zh) | 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法 | |
CN112225732B (zh) | 一种盐酸哌罗匹隆水合物晶型及其制备方法 | |
WO2014193881A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
WO2014193865A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN105985252B (zh) | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 | |
CN107954947A (zh) | 沃替西汀氢溴酸盐晶型c及其制备方法 | |
CN110407827B (zh) | Gcc-4401c的晶形和包含所述晶形的药物组合物 | |
CN109438388B (zh) | 具有降糖作用化合物的晶型及制备方法和含其的组合物 | |
CN112110850B (zh) | 一种苯磺酸左旋氨氯地平新晶型 | |
CN109651349B (zh) | 磺胺类化合物的新晶型以及制备方法和应用 | |
WO2017015784A1 (zh) | 奥比特嗪-富马酸盐、水合物、晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Si Shuyi Inventor after: Fu Miaoqing Inventor after: Zhou Haiyang Inventor after: Zhang Xuemei Inventor after: Guo Lijuan Inventor after: Yi Maocong Inventor before: Zhou Haiyang Inventor before: Zhang Xuemei Inventor before: Guo Lijuan Inventor before: Yi Maocong |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210916 Address after: Room 401, 4th floor, scientific research building, No.10 Shennong Road, Torch Development Zone, Zhongshan City, Guangdong Province 528400 Applicant after: Guangdong saifaluo Pharmaceutical Co.,Ltd. Address before: 255129 No.26, Kunxin Road, Kui Si Village, Kunlun town, Zichuan District, Zibo City, Shandong Province Applicant before: Shandong Jincheng Kunlun Pharmaceutical Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210226 |